eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

2/2020
vol. 12
 
Share:
Share:
more
 
 
Case report

Interstitial high-dose-rate brachytherapy as a boost in synchronous prostate and rectal cancer treatment: case report and literature review

Katarzyna Konat-Bąska
1, 2
,
Adam Chicheł
3
,
Urszula Staszek-Szewczyk
1, 2
,
Adam Maciejczyk
1, 2
,
Rafał Matkowski
1, 2

1.
Wroclaw Comprehensive Cancer Center, Poland
2.
Department of Oncology, Wroclaw Medical University, Poland
3.
Brachytherapy Department, Greater Poland Cancer Center, Poznan, Poland
J Contemp Brachytherapy 2020; 12, 2: 181–187
Online publish date: 2020/04/30
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Purpose

According to data from Polish National Cancer Registry, prostate and colorectal cancers are the first and the third most popular malignancies in male population. In 2015, the incidence of prostate tumor accounted for 17% and colorectal cancer for 15% of all cancers among male population [1]. Patient’s oncological awareness, screening programs, and increasing incidence rates of both above mentioned diseases lead to more frequent diagnosis of metachronous and/or synchronous prostate and rectal cancers. In 2015, in Lower Silesia Voivodeship, 9.1% of all cancers (1,204 cases) were diagnosed as multiple primary tumors, and 8.1% of them (98 cases) developed synchronously within 2 months. At that time, less than 10 cases of synchronous prostate and rectal cancer in our region were noted [2].

Patients with synchronous cancers usually report symptoms caused by rectal tumor and during additional exams, prostate cancer is unexpectedly diagnosed [3]. Due to the rarity of such cases, there are no standard treatment recommendations, and oncologists in multidisciplinary treatment teams (MTTs) need to provide an optimal curative management for two different cancers, with an acceptable risk of adverse effects to maintain the patient’s quality of life. Each of these cancers require different treatment approaches including surgery, chemotherapy, androgen deprivation therapy (ADT), and radiotherapy with external beam radiotherapy (EBRT) or low-dose-rate (LDR)/high-dose-rate (HDR) brachytherapy (BT). This case report describes different option of radical one-step treatment of synchronously diagnosed prostate and rectal cancer with the use of preoperative radio-chemotherapy for rectal cancer and HDR brachytherapy boost for prostate cancer.

Material and methods

Data of a 61-years-old patient with good performance status, diagnosed in Lower Silesian Oncology Center in 2015 with synchronous prostate and rectal cancer, treated with HDR brachytherapy boost for prostate were collected. Both cancers were locally advanced and staged with AJCC 7th edition (2010) as rectal cT3N2M0 and prostate cT2cN0M0 adenocarcinomas, Gleason score 3 + 3 = 6, with maximum prostate specific antigen (PSA) level of 21.84 ng/ml (Table 1). Clinical staging was performed with pelvic magnetic resonance imaging (MRI), digital rectal examination, PSA serum level, colonoscopy, chest X-ray, and bone scan. Histological diagnosis was confirmed with trans-rectal prostate biopsy and endoscopic rectal biopsy. The NCCN, ESMO, GEC-ESTRO, ABS, and institutional guidelines were used to determine treatment strategy. MTT consisted of urologist, radiation oncologist, clinical oncologist, and oncological surgeon decided on synchronous radical treatment of both cancers. The patient was qualified for a long-term (3 years) ADT, chemoradiation, and surgery. Before starting the treatment, gold seed fiducials were implanted to prostate gland in order to perform image-guided radiation therapy (IGRT). For androgen deprivation therapy, a first-generation antiandrogen (flutamide) was administered for one month to prevent testosterone flare, followed by 2-3 years of LHRH analogue. External beam radiation therapy (EBRT) to a total dose of 50.4 Gy in 28 fractions was delivered with image-guided intensity modulated radiation therapy. Irradiated volume included prostate gland with the base (defined on MRI), rectal tumor with margin (defined on digital rectal examination, colonoscopy, computed tomography, and MRI), seminal vesicles, mesorectum, common iliac nodes below L5-S1 interspace, external and internal iliac nodes, and presacral and obturator nodes (Figure 1). According to our institution’s IGRT protocol, 7 mm margin around prostate contour was added, except for margin in rectum, which was 3-5 mm to create planning target volume (PTV). During the course of radiotherapy, clinical target volume was matched to prostate gland on cone beam computed tomography (CBCT) and then, the adjustment to gold fiducials was performed. The patient was requested to drink 500 ml of water, 30 minutes before radiation, as before CT planning. CBCT was performed on 1st, 2nd, and 3rd day of radiation, and then weekly to check the reproducibility of bladder filling. If not, the patient was asked to fill the bladder more. Long-course chemotherapy regimen based on 5-fluorouracil was administrated concurrently with radiation. Additional dose of 15 Gy in a single fraction was delivered within a week after EBRT to prostate volume with interstitial HDR brachytherapy (transrectal ultrasound-based 3D real-time planning for Iridium-192, MicroSelectron afterloader; Oncentra Prostate®, Nucletron, Veenendal, The Netherlands) (Figure 2). The brachytherapy boost was administrated in Greater Poland Cancer Center.

Table 1

Patient characteristic

ParameterPatient
Age61
First symptomsDiarrhea, blood in stool, fatigue, loss of appetite, weight loss (18 kg in 4 months)
Prostate cancer featuresAdenocarcinoma, Gleason score 3 + 3 = 6 (15% cores from left lobe and 10% cores from right lobe), cT2cN0M0
Rectal cancer featuresAdenocarcinoma (unknown grade), cT3N2M0
Initial PSA level21.84 ng/ml
Initial CEA levelNot reported
Performance statusWHO: 1
ComorbiditiesBenign skin tumor – infraorbital area, amblyacousia
Neoadjuvant chemotherapyLF1
HormonotherapyLHRH analogue for 3 years
External beam radiation therapy dose to pelvis [Gy]PTV: 50.4 Gy/1.8 Gy
OARs:
Bladder: Dmax: 52.4 Gy
Small bowel: Dmax: 52.36 Gy
V45Gy: 104 cm3
HDR brachytherapy boost to prostate dose [Gy]192Ir, 15 Gy/1 fx one week after EBRT
Surgery typeSphincter-sparing, anterior resection (AR) with total mesorectal excision (TME) with end to end rectosigmoid anastomosis
Fig. 1

Excerpt from the EBRT treatment plan. A) Cross section plane: red line – PTV, cyan – bladder, violet – prostate with seminal vesicles, pink – rectum with tumor; B) Sagittal section plane: red line – PTV, cyan – bladder, violet – prostate with seminal vesicles, pink – rectum; C) Cross section color wash plane 95% isodose covering PTV; D) Three-dimensional view of the irradiated volume (PTV – red color)

/f/fulltexts/JCB/40414/JCB-12-40414-g001_min.jpg
Fig. 2

Excerpt from the HDR brachytherapy treatment plan. A) Cross section reference plane: red line – prostate contour, yellow – urethra, blue – rectum, red dots – source positions; B) Cross section isodose color wash representing their relations to prostate, urethra, and rectum contours: blue – 90% isodose, light green – 100% isodose, yellow – 150% isodose, orange – 200% isodose; C, D) Three-dimensional right-oblique and coronal views of the volumes of interest along with the spatial source positions’ distribution inside the prostate volume

/f/fulltexts/JCB/40414/JCB-12-40414-g002_min.jpg

Planned target dosimetry constraints for EBRT were verified according to the QUANTEC guidelines [4], and for prostate brachytherapy according the GEC-ESTRO, ABS and institutional guidelines (prostate D90 > 90%, V200 < 15%, Dmax lowest achievable; urethra D10 < 125%, Dmax < 160%; rectum D10 < 75%, Dmax < 100% of prescribed dose; bladder constraints: not reported at time of treatment; Table 2) [5,6]. Acute and late gastrointestinal and genitourinary toxicities were evaluated with the National Cancer Institute common terminology criteria for adverse events (CTCAE), version 4.0. Follow-up included physical examination, digital rectal examination, MRI, CT, colonoscopy, PSA, and carcino-embryonic antigen (CEA) concentration, according to guidelines [7].

Table 2

Brachytherapy treatment details

Doses reported in HDR prostate brachytherapy
Reference dose 15 Gy
D9099.95%
Dmax410.64%
V10089.97%
V15033.36%
V2004.32%
Urethra D10118.46%
Urethra Dmax131.26%
Rectum D1068.44%
Rectum Dmax85.86%
BladderNot assessed
Prostate volume25 ml
Number of needles used25
IPSS at time of BT18 points

Results

Treatment tolerance of preoperative radiochemotherapy was good until the 20th fraction of radiation. The patient reported only nocturia 2-3 times by night. After the 20th radiotherapy fraction, the patient developed acute diarrhea with dehydration and hypokalemia. For 5 consecutive days, radiochemotherapy was paused. Following the break, the patient received total originally planned dose of radiotherapy. No supplemental EBRT fractions were added because of planned additional brachytherapy boost and surgery. There were no other acute genitourinary (GU) and gastrointestinal (GI) toxicities reported. Within a week, HDR-BT boost was administered (Table 2). Eight weeks after the completion of EBRT, the patient underwent sphincter-sparing, anterior resection (AR), and total mesorectal excision (TME) with end-to-end rectosigmoid anastomosis. The tolerance of surgery was good, with no toxicities reported.

Twenty-five months after the completion of surgery, GU or GI toxicities were not observed, and PSA level was 0.059 ng/ml. At that time of follow-up, post-treatment CT scans showed no evidence of recurrence. Currently, the patient is 45 months after the surgery. Hormonal treatment was terminated after 36 months and actual PSA level is < 0.003 ng/ml, with no GU or GI toxicities reported. Physical examination as well as imaging revealed no symptoms of local recurrence or distant metastases. Up till date, no signs of disease recurrence were reported by patient, nor revealed by physical examination. Performed imaging showed complete response, with no local recurrence or distant metastases.

Discussion

Since synchronous prostate and rectal cancers are rare cases, there is a lack of publications about one-step radical treatment approach for this kind of patients. All available papers are case reports or case series [3,8,9,10,11,12].

Lin et al. reported tree cases of Chinese men with synchronous prostate and rectal cancer safely treated with surgery including lower anterior resection (LAR) or abdominoperineal resection (APR) with radical retropubic prostatectomy (RRP) performed in a single operation [12]. Seretis et al. [3] in their review of literature presented the largest group of patients (n = 23) with synchronous prostate and rectal cancer. Most of patients (n = 8) were treated only surgically: prostatectomy with APR or LAR, depending on rectal tumor location. Only two patients received preoperative radiation therapy with APR, but rectal cancer staging was not assessed; therefore, it cannot be determined whether this was a correct approach. Only one patient in stage III (cT3N1) rectal cancer was treated according to current guidelines with preoperative radiochemotherapy. In this case, prostate cancer was treated with radiotherapy, with an additional dose to total 70 Gy prescribed to prostate field. There were no post-operative complications reported and during 14 months follow-up, patient was asymptomatic, with PSA level of 0.3 ng/ml [8]. Lavan et al. [10] analyzed 10 cases with synchronous prostate and rectal cancer, simultaneously treated for both tumors in 3 centers, using so called “shrinking field radiotherapy” including EBRT (45-50.4 Gy) for pelvic area and an additional dose to prostate (up to total dose of 70.0-79.2 Gy) with concurrent 5-FU chemotherapy. Nine of ten patients underwent surgery: anterior resection (AR) or APR, and one patient declined the surgery. Follow-up was assessed from initial diagnosis for median 2.2 years (range, 1.2-6.3 years). Five of nine patients had no evidence of disease during follow-up, other four were living with a metastatic disease. Two patients reported with significant late toxicity: first grade 3 GU toxicity (proctitis) and second grade 3 GI toxicity (anastomotic stricture). Qiu et al. [11] presented case series of 4 patients with synchronous cT3N1 rectal and cT1c prostate cancer, treated with chemoradiation, prostate brachytherapy boost, and surgery, followed by adjuvant chemotherapy. Initial dose of 45 Gy/1.8 Gy per fraction delivered with 3D EBRT encompassed the prostate gland, whole seminal vesicles, rectal tumor, internal iliac, external iliac, presacral, and perirectal lymph nodes. Three patients received additional dose to 54 Gy/1.8 Gy to the rectal gross tumor volume and sacral hollow, plus 1 cm planning target volume expansion with IMRT. Within 23-41 days after EBRT, all patients received additional dose of Cesium-131 (131Cs)-based LDR prostate brachytherapy to a prescribed target dose of 80-90 Gy, with dosimetry constrains for prostate V100 ≥ 90%, urethra D30 < 150%, and rectal V100 < 0.5 cc. After 2-4 weeks, patients underwent LAR with diverting loop ileostomy and 4-6 weeks later, adjuvant chemotherapy was applied. One patient from high-risk group prostate cancer received androgen deprivation therapy. Six to eight months after surgery, patients’ ileostomies were reversed. According to CTCAE criteria, first patient was observed with grade 1 GU, second with grade 1 GI toxicity, third with grade 2 GU and GI, and fourth patient was noted with grade 3 GI toxicity.

To the best of our knowledge, the current case report is the first of its kind to describe the utilization of HDR brachytherapy boost in the radical treatment of synchronous prostate and rectal cancers. According to the NCCN risk categories, our patient was in high-risk group, because of elevated PSA level and expected survival of more than 5 years. In this case, the patient should receive radical prostatectomy (RP) with nodal dissection or EBRT ± brachytherapy boost with long-term ADT (2-3 years) [13].

In terms of rectal cancer, the patient was qualified into bad-risk group, for which, according to the ESMO guidelines, 2013, treatment options included preoperative “short” course of RT or chemoradiotherapy (CRT), followed by total mesorectal excision (TME) [14].

The way our patient was treated connected two radical methods of treatment presented above. The patient was qualified for a long-term ADT, preoperative chemoradiation, in which PTV contained both prostate and rectum areas with appropriate nodal regions, and additional dose to prostate region delivered with HDR brachytherapy boost; after completion of that treatment, TME was performed.

This approach generated few problems with external beam radiotherapy planning such as an extent of irradiated area, a proper choice of sufficient dose and the best method of radiation delivery, minimizing the toxicity and maintaining or improving patient’s quality of life.

During preoperative radiotherapy in rectal cancer, the CTV encompasses tumor with appropriate margin, and peri-rectal, pre-sacral, and internal iliac nodal regions [15,16,17]. High-risk prostate cancer treatment with radiation therapy requires not only prostate gland with seminal vesicles volume irradiation, but also an addition of regional lymph node area, which involves common and internal iliac, pre-sacral and obturator nodal regions [18,19]. Irradiated volumes for these two types of cancers are in square or in close proximity with each other. Because of this, there is a technical opportunity to irradiate two CTVs for separate cancers in one volume.

In terms of radiation therapy in rectal cancer during treatment planning for our patient, there were two main preoperative dose schedules with 25 Gy/5 Gy per fraction without chemotherapy, or 50.4 Gy/1.8 Gy per fraction with chemotherapy, for more advanced tumors [14]. Regarding an elective nodal irradiation for prostate cancer, a dose of 50.4 Gy/1.8 Gy per fraction is high enough. Ablative doses in radical prostate cancer treatment are higher, because of low α/β ratio (approximately 1.5) of prostate adenocarcinomas [20]. In conventionally fractionated radiotherapy doses up to 76-80 Gy/2 Gy per fraction, which corresponds to biologically equivalent dose (BED1.5) of 180-200 Gy, improve disease control [21]. Higher dose to prostate volume may be delivered with few techniques including EBRT with “shrinking field technique”, standard fractionation or hypofractionation, and brachytherapy boost LDR or HDR.

As a standard of care, there are few rationales for using brachytherapy boost among patients with intermediate- and high-risk prostate cancer. HDR-BT boosts plans to the prostate are more conformal in comparison to IMRT plans [22]. BT, especially HDR when used as the only treatment modality, can spare dose to normal tissues, as compared to other techniques like volumetric modulated arc therapy (VMAT), scanned proton therapy (intensity-modulated proton therapy – IMPT), and scanned carbon-ion therapy (intensity-modulated carbonion therapy) [23].

LDR brachytherapy boost in comparison to dose escalated EBRT (DE-EBRT) (up to 78 Gy) for intermediate- and high-risk prostate cancer in ASCENDE-RT randomized trial revealed an improvement in bPFS, with no significant overall survival difference [24]. Additionally, median 6.5 years follow-up in this trial showed higher incidence of acute and late GU morbidities after LDR prostate brachytherapy boost, and non-significant tendency for worse GI morbidity [25].

Retrospective analysis using data from the National Cancer Database revealed statistically significant improvement in overall survival, when using LDR-BT boost among patients with unfavorable prostate cancer [26].

Similarly, there is meta-analysis comparing EBRT vs. BT boost for intermediate- and high-risk prostate cancer, suggesting BT boost as level I and grade A treatment recommendation (b-PFS improvement, with no difference at 5 years in overall survival). In terms of grade ≥ 3 late toxicity, meta-analysis suggested further investigations [27].

At Poland, there is a problem with LDR permanent seeds brachytherapy treatment reimbursement, and the access to this kind of treatment is limited. HDR brachytherapy is refunded, more popular, and widely accessible. The question is whether we can use HDR instead of LDR-BT boost with similar efficacy and equal or fewer adverse effects level? In phase 2 randomized pilot study comparing first 12 months of HDR and LDR brachytherapy as monotherapy, HDR-BT had lower urinary toxicity profile and higher QoL level [28].

The National Cancer Database analysis revealed HDR brachytherapy boost for prostate cancer as a good alternative for LDR boost in terms of improving overall survival [29]. Toxicity profile also seems to be acceptable, even if hypofractionated EBRT (37.5 Gy/15 fractions) with one HDR-BRT boost fraction (15 Gy/1 fraction) is prescribed (grade 3 or higher late toxicity rate of < 5%) [30].

However, there is a large SEER-based study, which reported non-statistically significant increase in grade 3 GU toxicity among patients treated with combination of EBRT with BT boost, both LDR and HDR (greater with HDR) [31]. In addition, we need to wait for results from currently ongoing BrachyQoL randomized controlled trial (NCT01936883), which directly compares short- and long-term toxicity profiles between LDR and HDR-BT boost approaches [32].

Our case report on HDR-BT boost proved to have safe toxicity profile, even when treating synchronous prostate and rectal cancer with additional chemotherapy and surgery.

Conclusions

Despite synchronous diagnosis of two different cancers, coordinated work of multidisciplinary treatment team helped to find radical treatment modality for both the diseases. Combination of androgen deprivation therapy, chemo-radiotherapy, brachytherapy, and surgery proved to be feasible and safe with good oncological outcome (over 45 months of local, regional, and biochemical control).

HDR brachytherapy as a boost seems to be well-tolerated and effective option for delivering proper treatment dose to prostate in case of simultaneous treatment of rectal and prostate cancer. Undoubtedly, further observations with greater number of patients is needed, where HDR brachytherapy boost toxicity profile treatment is thoroughly investigated.

Disclosure

This study was funded by a statutory subsidy by the Polish Ministry of Science and Higher Education as part of grant SUB.C280.19.050 (record numbers in the Simple system).

Authors report no conflict of interest.

References

1 

Wojciechowska U. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie. http://onkologia.org.pl/raporty/ (accessed: 20.11.2019).

2 

Błaszczyk JJagas MHudziec P. Nowotwory złośliwe w woj. dolnośląskim w roku 2015. Dolnośląski Rejestr Nowotworów, Dolnośląskie Centrum Onkologii we Wrocławiu.

3 

Seretis CSeretis FLiakos N. Multidisciplinary approach to synchronous prostate and rectal cancer: current experience and future challenges. J Clin Med Res 2014; 6: 157-161.

4 

Marks LBYorke EDJackson Aet al.. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76 (3 Suppl): S10-19.

5 

Hoskin PKovács Gvan Vulpen Met al.. The GEC ESTRO handbook of brachytherapy: prostate cancer. 2014.

6 

Yamada YRogers LDemanes DJet al.. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012; 11: 20-32.

7 

Jassem Jet al.. Badania kontrolne po leczeniu w najczęstszych nowotworach litych u dorosłych. Nowotwory 2014; 64: 415-435.

8 

Colonias AFarinash LMiller Let al.. Multidisciplinary treatment of synchronous primary rectal and prostate cancers. Nat Clin Pract Oncol 2005; 2: 271-274.

9 

Villegas-Otiniano PVásquez-Medina JBenites-Zapata VA. Synchronous prostate and rectal cancer, a case report. Rep Pract Oncol Radiother 2018; 23: 458-461.

10 

Lavan NAKavanagh DOMartin Jet al.. The curative management of synchronous rectal and prostate cancer. Br J Radiol 2016; 89: 20150292.

11 

Qiu HHerman JMAhuja Net al.. Neoadjuvant chemoradiation followed by interstitial prostate brachytherapy for synchronous prostate and rectal cancer. Pract Radiat Oncol 2012; 2: e77-84.

12 

Lin CJin KHua Het al.. Synchronous primary carcinomas of the rectum and prostate: Report of three cases. Oncol Lett 2011; 2: 817-819.

13 

Armstrong AJet al.. NCCN Guidelines Panel Disclosures Prostate Cancer NCCN Evidence Blocks TM. 2019.

14 

Glynne-Jones RWyrwicz LTiret Eet al.. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv22-40.

15 

Valentini VGambacorta MABarbaro Bet al.. Clinical target volume (CTV) and organs. Radiother Oncol 2016; 120: 195-201.

16 

Myerson RGarofalo MIel Nagaet al.. Elective clinical target volumes in anorectal cancer: an RTOG consensus panel contouring atlas; https://www.rtog.org/LinkClick.aspx?fileticket=DgflROvKQ6w%3d&tabid=231 (accessed: 20.11.2019).

17 

Lee NYRiaz NNadeem Let al.. Target volume delineation for conformal and intensity-modulated radiation therapy. DOI: 10.1007/174_2014_979.

18 

Salembier CVilleirs GDe Bari Bet al.. ESTRO ACROP consensus guideline on CT-and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol 2018; 127: 49-61.

19 

Harris VAStaffurth JNaismith Oet al.. Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2015; 92: 874-883.

20 

Brenner DJHall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095-1101.

21 

Zaorsky NGPalmer JDHurwitz MDet al.. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol 2015; 115: 295-300.

22 

Hermesse JBiver SJansen Net al.. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate. Int J Radiat Oncol Biol Phys 2010; 76: 269-276.

23 

Georg DHopfgartner JGora Jet al.. Physics contribution dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy radiation oncology. Int J Radiat Oncol Biol Phys 2014; 88: 715-722.

24 

Morris WJTyldesley SRodda Set al.. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost. Int J Radiat Oncol Biol Phys 2017; 98: 275-285.

25 

Rodda STyldesley SMorris WJet al.. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high-and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 286-295.

26 

Johnson SBLester-Coll NHKelly JRet al.. Brachytherapy boost utilization and survival in unfavorable-risk prostate cancer. Eur Urol 2017; 72: 738-744.

27 

Kee DLCGal JFalk ATet al.. Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials. Cancer Treat Rev 2018; 70: 265-271.

28 

Hathout LMahmoud OWang Yet al.. A phase 2 randomized pilot study comparing high-dose-rate brachytherapy and low-dose-rate brachytherapy as monotherapy in localized prostate cancer. Adv Radiat Oncol 2019; 4: 631-640.

29 

King MTYang DDMuralidhar Vet al.. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy 2019; 18: 186-191.

30 

Morton GC. High-dose-rate brachytherapy boost for prostate cancer: rationale and technique. J Contemp Brachytherapy 2014; 6: 323-330.

31 

Tward JDJarosek SChu Het al.. Time course and accumulated risk of severe urinary adverse events after high-versus low-dose-rate prostate brachytherapy with or without external beam radiation therapy. Int J Radiat Oncol Biol Phys 2016; 95: 1443-1453.

32 

Improving quality of life after prostate brachytherapy: a comparison of HDR and LDR brachytherapy. https://clinicaltrials.gov/ct2/show/NCT01936883 (accessed: 20.11.2019).

Copyright: © 2020 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe